Although classic PARPis can selectively eliminate BRCA1/2‐deficient cancer cells by inducing SL, their clinical efficacy is hampered by inherent limitations: a subset of patients harbouring BRCA1/2 mutations exhibit primary non‐responsiveness to PARPis, and the majority develop acquired resistance over the course of treatment.9 This evidence concerns the gene BRCA1 and cancer.